IPO - BAKER BROS. ADVISORS LP

Form Type: SCHEDULE 13D/A

Filing Date: 2025-06-30

Corporate Action: Ipo

Type: Update

Accession Number: 000110465925064298

Filing Summary: This document amends and supplements the previously filed Schedule 13D by Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, and Felix J. Baker. On June 26, 2025, Kymera Therapeutics, Inc. entered into an underwriting agreement related to a public offering of 5,044,500 shares of common stock priced at $44.00 per share, alongside prefunded warrants for 655,500 shares at a price of $43.9999. The offering closed on June 30, 2025. The funds managed by Baker Bros. Advisors purchased a total of 655,500 shares and accompanying prefunded warrants using their working capital. Additional terms regarding the management of security holdings and options, as well as insights into beneficial ownership limitations were discussed, emphasizing the discretionary authority of the advisor over the investments. Felix J. Baker received stock options, and a registration rights agreement was established with the issuer granting the funds resale registration rights for their securities, which will remain in effect for up to ten years following a specified effective date. A lock-up agreement was also established with Felix Baker regarding the sale of his common stock until September 24, 2025.

Form Type: SCHEDULE 13D

Filing Date: 2025-02-14

Corporate Action: Ipo

Type: Update

Accession Number: 000110465925014220

Filing Summary: Baker Bros. Advisors LP has filed an updated Schedule 13D concerning Sera Prognostics, Inc. on February 14, 2025. This filing outlines that the Funds under the management of Baker Bros. Advisors have acquired a significant amount of shares and warrants related to the Issuer's equity offerings. Specifically, the document states that the Issuer entered into an Underwriting Agreement on February 10, 2025, which led to a public offering of 1,250,000 shares at a price of $4.00 per share and 11,250,000 Pre-Funded Warrants at a price of $3.9999 per share. These securities were purchased with the working capital of the Funds on the open market and in transactions with underwriters, suggesting ongoing investment activity and confidence in the growth of Sera Prognostics. The aggregate purchase price noted for the securities held by the Funds is approximately $89,225,596. The filing also mentions that both Julian C. Baker and Felix J. Baker, as managing members, are actively involved in the decision-making process regarding the investments. Furthermore, there are provisions concerning registration rights associated with the shares acquired, indicating strategic plans for future liquidity and flexibility in managing their ownership stake.